APLS - Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting | Benzinga
WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that 14 abstracts, 11 of which are oral presentations, will be presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held May 5 - 9 in Seattle. The data continue to reinforce the robust efficacy and safety profile of SYFOVRE® (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
"The 11 oral presentations at ARVO speak to the continued excitement surrounding SYFOVRE, which is the most chosen GA treatment by retina specialists," said Caroline Baumal, M.D., chief medical officer, Apellis. "We are excited to share data that continue to highlight SYFOVRE's ability to slow disease progression with increasing effects over time and its potential to preserve visual function longer."
Oral presentations:
- Long-term efficacy and safety of pegcetacoplan over 36 months: results from 12 months of the GALE open-label extension study – Ashkan Abbey, M.D. – Sunday, May 5 – 1:45?2:00 PM PDT (encore)
- Pegcetacoplan vs avacincaptad pegol in geographic atrophy: an anchored matching-adjusted indirect comparison of three phase 3 trials – Marco Zarbin, M.D., Ph.D. – Thursday, May 9 – 2:15?2:30 PM PDT (encore)
- Pegcetacoplan delays time to loss of central macular sensitivity: a microperimetry analysis of the phase 3 OAKS study – Rishi Singh, M.D., FASRS – Thursday, May 9 – 3:30?3:45 PM PDT (encore)
- The SD-OCT correlates of fundus autofluorescence in geographic atrophy: a comprehensive point-to-point analysis of fundus autofluorescence with SD-OCT using phase 3 trials DERBY and OAKS – Konstantinos Balaskas, M.D. – Sunday, May 5 – 2:15?2:30 PM PDT
- Variability of perilesional FAF patterns associated with automated OCT-based PR/RPE loss ratios in GA progression in the phase 3 OAKS/DERBY trials – Julia Mai, M.D. – Sunday, May 5 – 4:45?5:00 PM PDT
- Contrast sensitivity function using a prototype gaze tracking-based virtual reality headset in age-related macular degeneration (AMD) – Deepayan Kar, Ph.D., MS – Monday, May 6 – 8:30?8:45 AM PDT
- A deep-learning approach to identifying quantitative OCT biomarkers predictive of visual deficit measured by microperimetry at 24 months in OAKS trial – Dun Jack Fu, Ph.D., BMBCh – Tuesday, May 7 – 9:30?9:45 AM PDT
- AI-based qOCT analysis of phase 3 trials OAKS & DERBY data on the effect of pegcetacoplan on geographic atrophy – Pallavi Bagga, Ph.D. – Tuesday, May 7 – 2:15?2:30 PM PDT
- Predictive value of the photoreceptor/RPE loss ratio on OCT in the management of geographic atrophy (GA) for patient selection and monitoring of therapeutic efficacy – Ursula Schmidt?Erfurth, M.D. – Tuesday, May 7 – 2:30?2:45 PM PDT
- Rate of response ...